<DOC>
	<DOC>NCT02420730</DOC>
	<brief_summary>This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3 different concentrations of AGN-232411 topical ophthalmic solution in healthy participants and participants with dry eye.</brief_summary>
	<brief_title>Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Inclusion criteria: Stage 1 Healthy participants. Stage 2 Participants with the symptoms of dry eye disease. Exclusion criteria: Stage 1 Known allergies or sensitivities to study medications, fluorescein, or lissamine green Stage 2 Known allergies or sensitivities to study medications, fluorescein, or lissamine green Allergic ocular disease, ocular trauma, corneal erosions or ulcers, or uveitis within the previous 12 months History of any ocular surgery within the previous 12 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>